Chronic Lymphocytic Leukaemia
Does the Addition of Mitoxantrone Improve Response to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without mitoxantrone (M) in previously untreated chronic lymphocytic leukaemia
Genetic study of B-cell chronic lymphocytic leukaemia and other lymphoproliferative disease.
CLL Lenalidomide Maintanence 002 - The Continuum Trial
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) AS MAINTENANCE THERAPY FOR PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA FOLLOWING SECOND-LINE THERAPY (The Continuum Trial)
A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukaemia
Primary Outcome Measures:
•Progression-free-survival (PFS)
Secondary Outcome Measures:
•Overall response rate
•Overall survival
•Clinical benefit, safety, tolerability, changes in patient reported outcome measures and pharmacokinetics
A Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH®, MabCampath®) in Patients with Previously Treated B-Cell Chronic Lymphocytic Leukemia
Attenuated dose Rituximab with ChemoTherapy In CLL: A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR)
A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Study Of The Safety And Efficacy Of Different Lenalidomide (Revlimid®) Dose Regimens In Subjects With Relapsed Or Refractory B-Cell Chronic Lymphocytic Leukemia